Meta-Analysis of Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement

Transcatheter aortic valve replacement (TAVR) has evolved as an important treatment option for patients with severe symptomatic aortic stenosis. Despite advancements with device design, procedural techniques, and improved operator experience, stroke rates after TAVR have not declined( ∼2.5%), as per the recent data from the national cardiovascular database registry.1 Embolic protection devices (EPDs) were introduced to prevent embolization of thrombotic or calcified debris during TAVR. However, randomized controlled trials (RCTs) that investigated the efficacy and safety of the se devices have been underpowered for clinical endpoints.

Source: The American Journal of Cardiology - October 23, 2020 Category: Cardiology Authors: Salik Nazir, Fnu Zafrullah, Hafeez U.H. Virk, Charnjeet Singh Sandhu, Muhammad Ameen, Keerat Rai Ahuja Source Type: research